Financial Survey: Viveve Medical (VIVE) & Accuray (ARAY)

Viveve Medical (NASDAQ: VIVE) and Accuray (NASDAQ:ARAY) are both small-cap advanced medical equipment & technology – nec companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Risk & Volatility

Viveve Medical has a beta of -0.59, meaning that its stock price is 159% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Viveve Medical and Accuray, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viveve Medical 0 0 4 0 3.00
Accuray 0 3 3 0 2.50

Viveve Medical currently has a consensus price target of $10.50, indicating a potential upside of 109.58%. Accuray has a consensus price target of $6.60, indicating a potential upside of 41.94%. Given Viveve Medical’s stronger consensus rating and higher possible upside, analysts clearly believe Viveve Medical is more favorable than Accuray.

Earnings & Valuation

This table compares Viveve Medical and Accuray’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Viveve Medical $7.14 million 13.63 -$20.11 million ($2.12) -2.36
Accuray $383.41 million 1.02 -$29.57 million ($0.34) -13.68

Viveve Medical has higher revenue, but lower earnings than Accuray. Accuray is trading at a lower price-to-earnings ratio than Viveve Medical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

65.6% of Viveve Medical shares are owned by institutional investors. Comparatively, 74.9% of Accuray shares are owned by institutional investors. 35.1% of Viveve Medical shares are owned by insiders. Comparatively, 3.9% of Accuray shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


This table compares Viveve Medical and Accuray’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Viveve Medical -257.58% -275.77% -102.12%
Accuray -7.49% -55.18% -6.33%


Accuray beats Viveve Medical on 7 of the 13 factors compared between the two stocks.

About Viveve Medical

Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician’s office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.

About Accuray

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with's FREE daily email newsletter.

Leave a Reply